has been refreshed! Take a tour.
  • Meningococcal ACWY
  • For People with Risk Factors

Does the recommendation for separation of DTaP and Menactra (MenACWY-D) also apply to children with functional or anatomic asplenia?

Yes. The recommendation about spacing of DTaP and Menactra (MenACWY-D) applies to all children younger than 7 years with a high-risk condition for meningococcal disease, including travelers. Menactra may be used earlier than 6 months after DTaP if it is the only available option and vaccination is necessary due to travel to an area with epidemic or hyperendemic meningococcal disease. Menveo (MenACWY-CRM) and MenQuadfi (MenACWY-TT) may be given at any time before or after DTaP.

Last reviewed: July 15, 2023

This page was updated on .